Authors

Latest:

Health Care Resource Utilization and Transition of Care

Panelists discuss routine laboratory monitoring for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) as well as insights from the American Society of Hematology Annual Meeting and Exposition (ASH 2024) data on health care resource utilization and costs associated with administering chimeric antigen receptor (CAR) T-cell therapy and managing related toxicities.

Andrew Ip, MD, MS

Latest:

Dr. Ip on the Utility of Investigational Treatments for COVID-19 in Oncology

Andrew Ip, MD, MS, discusses the utility of investigational treatments for COVID-19 in patients with cancer.

David Sommerhalder, MD

Latest:

Dr Sommerhalder on the Potential Utility of Single-Agent RMC-6291 in KRAS G12C–Mutant CRC

David Sommerhalder, MD, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer.

Julia Liu, MD

Latest:

Dr. Liu on Enrolling Diverse Patients in the PREEMPT-CRC Trial in CRC

Julia Liu, MD, discusses enrolling diverse patients in the PREEMPT CRC trial in colorectal cancer.

Martin Cannon, PhD

Latest:

Dr Cannon on the Use of Dendritic Cell Vaccines in Ovarian Cancer

Martin Cannon, PhD, discusses the use of dendritic cell vaccines and immune checkpoint inhibitors in ovarian cancer.

Stephen Bagley, MD, MSCE

Latest:

Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas

Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.

Peter Hillmen, MD, PhD

Latest:

Dr. Hillmen on Results With Acalabrutinib in CLL

Peter Hillmen, MD, PhD, discusses results reported with acalabrutinib in patients with chronic lymphocytic leukemia, as demonstrated in a phase 3 trial.

Mitchell Machtay, MD

Latest:

Dr Machtay on the Prognostic Value of Pre-Treatment Immunologic Biomarker Levels in NSCLC

Mitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.

Bhavana Bhatnagar, DO

Latest:

Dr Bhatnagar on AlloSCT Outcomes After Blinatumomab/Chemo in MRD-Negative B-ALL

Bhavana Bhatnagar, DO, discusses outcomes for allogeneic stem cell transplantation after blinatumomab plus chemotherapy in B-ALL.

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center

Latest:

Expanding Treatment Options for HER2+ Breast Cancer

David Weintritt, MD, FACS

Latest:

Empowering Breast Surgeons: A Call for Collective Action

As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.

Montefiore Einstein Comprehensive Cancer Center

Latest:

Montefiore Einstein Comprehensive Cancer Center Upholds Top Honor for Cancer Care

MECCC Earns Three-Year Accreditation from the Commission on Cancer of the American College of Surgeons – Again!

Idalid Franco, MD, MPH

Latest:

Dr Franco on the Integration of Immunotherapy Treatment in Endometrial Cancer

Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.

Judy Hayek, MD

Latest:

Dr Hayek on the Rationale of Assessing Laparoscopic Surgery in Advanced Ovarian Cancer

Judy Hayek, MD, explains the rationale of a retrospective analysis evaluating laparoscopic vs open surgery in advanced ovarian cancer.

Dejan Juric, MD, Massachusetts General Hospital

Latest:

Future Directions for the Management of HR+ Breast Cancer

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

Andrew Laccetti, MD, MS

Latest:

Dr Laccetti on PSA Responses With Masofaniten Plus Enzalutamide in mCRPC

Andrew Laccetti, MD, MS, discusses phase 1 findings from a phase 1/2 trial investigating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.

Anil K. Sood, MD

Latest:

Dr. Sood on Navigating Frontline Maintenance Therapy in Ovarian Cancer

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

Ori Barzilai, MD

Latest:

Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.

Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB

Latest:

Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.

Nicholas Coupe, MBBS, PhD

Latest:

Dr Coupe on the Background of IMM60 With Pembrolizumab in Melanoma or NSCLC

Nicholas Coupe, MBBS, PhD, discusses the rationale for investigating IMM60 with pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer, as well as key background information that led to this investigation.